



## Immatics Press Release

### Immatics Appoints Stephen Eck as Chief Medical Officer US

**Houston, Texas, May 14, 2018** – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. (Houston, Texas), effective immediately.

Stephen Eck is a hematologist and oncologist with more than 25 years experience in academia and industry. He began his professional career at the University of Pennsylvania where he was Director of the Gene Therapy Program, and has since held a number of leadership roles in oncology drug and biomarker development at prominent pharmaceutical companies. Prior to joining Immatics, Stephen Eck served as Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, and previously held senior roles at Pfizer and Eli Lilly.

Dr. Harpreet Singh, CEO and President of Immatics US, said: “Stephen’s appointment will further strengthen our cell therapy programs and global development capabilities. He brings significant experience in both early and late-stage development, as well as new drug approvals, in oncology and cancer immunotherapies, which will be invaluable to us as we progress our clinical and pre-clinical programs.”

Dr. Stephen Eck, Chief Medical Officer of Immatics US, said: “Immatics has truly impressed me as having one of the most innovative approaches in immuno-oncology. I am thrilled to be joining the Company at this very exciting time in its history, and as T-cell therapies move to become more widely used in cancer therapeutics. Immatics’ unique approach gets at the root cause of prior failures in the treatment of solid cancers by addressing novel, highly-specific cancer targets and mobilizing billions of activated T cells against these.”

Whilst at Astellas Pharma, Stephen Eck worked closely with The University of Texas MD Anderson Cancer Center, a key collaborator of Immatics, on a number of clinical trials, joint collaborations and external advisory committees. Notably, he is a member of MD Anderson’s Moon Shots Program™ advisory board. Additionally, he is a Fellow of the



American Association for the Advancement of Science, and is Chairman of the Board of Directors of the Personalized Medicine Coalition. Stephen Eck has a Ph.D. in Chemistry from Harvard University and an M.D. degree from the University of Mississippi School of Medicine.

### **About Immatics**

Immatics is a clinical-stage biopharmaceutical company spearheading the development of advanced immunotherapies that are active against multiple cancer indications. Based in Tuebingen, Germany, and Houston, Texas, the Company has recognized that better and safer targets are the key to developing future cancer immunotherapies. Immatics has revolutionized the identification and qualification of novel, proprietary and tumor-specific peptide antigens (TUMAPs) by developing its world-leading T-cell receptor (TCR) and target discovery platform XPRESIDENT®. TUMAPs significantly expand the target space for immune-oncology as they are not limited to surface proteins, which are the targets of classical antibodies or CAR-T therapies. Immatics believes that, by using its proprietary expertise, it can unlock the significant potential of immune-oncology drugs, such as adoptive cellular therapies, biologicals and vaccines to improve the treatment of a wide range of cancers.

Immatics' pipeline includes several T-cell therapy programs, including ACTolog® and ACTengine® which are developed in collaboration through Immatics US with MD Anderson Cancer Center, and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). The pipeline also includes a number of bispecific TCR molecules. By using its world-leading target and TCR discovery expertise, Immatics aims to deliver safer, best-in-class immunotherapies to cancer patients with high medical need in multiple indications.

For regular updates about Immatics, visit [www.immatics.com](http://www.immatics.com).

ACTolog®, ACTengine® and XPRESIDENT® are registered trademarks of Immatics Biotechnologies GmbH.

### **For more information, please contact:**

#### **Immatics Biotechnologies GmbH**

Dr. Nikola Wiegeler

Phone: +49 7071 5397-110